Teva Pharmaceutical Industries Limited (TEVA) announced that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application or ANDA to market its generic version of Takeda Pharmaceuticals North America Inc.'s Prevacid (Lansoprazole) SoluTab.
The Court found that Teva's generic lansoprazole orally disintegrating tablets do not infringe U.S. Patent . Teva said that it intends to complete an analysis of the decision before deciding upon its next course of action.
Annual sales of the brand product were about $500 million in the United States for the twelve months that ended June 30, 2009 based on IMS sales data.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.